...
首页> 外文期刊>ACS Omega >Mixed-Dimensional Heterostructure Material-Based SERS for Trace Level Identification of Breast Cancer-Derived Exosomes
【24h】

Mixed-Dimensional Heterostructure Material-Based SERS for Trace Level Identification of Breast Cancer-Derived Exosomes

机译:基于混合型异质结构材料的乳腺癌衍生出外瘤的痕量鉴定

获取原文
           

摘要

Raman spectroscopy has capability for fingerprint molecular identification with high sensitivity if weak Raman scattering signal can be enhanced by several orders of magnitudes. Herein, we report a heterostructure-based surface-enhanced Raman spectroscopy (SERS) platform using 2D graphene oxide (GO) and 0D plasmonic gold nanostar (GNS), with capability of Raman enhancement factor (EF) in the range of ~10~(10) via light–matter and matter–matter interactions. The current manuscript reveals huge Raman enhancement for heterostructure materials occurring via both electromagnetic enhancement mechanism though plasmonic GNS nanoparticle (EF ~10~(7)) and chemical enhancement mechanism through 2D-GO material (EF ~10~(2)). Finite-difference time-domain (FDTD) simulation data and experimental investigation indicate that GNS allows light to be concentrated into nanoscale “hotspots” formed on the heterostructure surface, which significantly enhanced Raman efficiency via a plasmon–exciton light coupling process. Notably, we have shown that mixed-dimensional heterostructure-based SERS can be used for tracking of cancer-derived exosomes from triple-negative breast cancer and HER2(+) breast cancer with a limit of detection (LOD) of 3.8 × 10~(2) exosomes/mL for TNBC-derived exosomes and 4.4 × 10~(2) exosomes/mL for HER2(+) breast cancer-derived exosomes.
机译:如果可以通过几个大小可以增强弱拉曼散射信号,则拉曼光谱具有具有高灵敏度的指纹分子识别能力。在此,我们通过2D石墨烯氧化物(GO)和0d等级金纳米骨(GNS)报告一种基于异结构的表面增强拉曼光谱(SERS)平台,其具有拉曼增强因子(EF)的能力在〜10〜( 10)通过浅品和物质相互作用。目前的手稿揭示了通过电磁增强机构发生的异性结构材料的巨大拉曼增强,通过2D-GO材料(EF〜10〜(2))和化学增强机制(EF〜10〜(2))。有限差分时间域(FDTD)仿真数据和实验研究表明GNS允许光集中到形成在异质结构表面上形成的纳米级“热点”中,这通过等离子体激发光耦合过程显着提高了拉曼效率。值得注意的是,我们已经表明,基于混合型异质结构的SERS可用于跟踪来自三阴性乳腺癌和HER2(+)乳腺癌的癌症衍生的外来,其检测限为3.8×10〜( 2)对于HER2(+)乳腺癌衍生的外泌体进行4.4×10〜(2)外泌体/ mL的外泌体/ ml。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号